Clinical trial NCT04069910: Stereotactic Radiation Therapy Before Surgery for the Treatment of Resectable Brain Metastases
Official title: Neoadjuvant Stereotactic Radiation Therapy for Resectable Brain Metastases
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Malignant Neoplasm, Brain
Brain Tumor
Lead sponsor: Jonsson Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2019-08-28
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial studies how well stereotactic radiation therapy before surgery works in treating patients with cancer that has spread to the brain (brain metastases) and can be removed by surgery (resectable). Stereotactic radiation therapy is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor, and may cause less damage to normal tissue. Giving stereotactic radiation therapy before surgery may make the return of brain metastases less likely and help patients live longer compared to surgery followed by radiation therapy.

Detailed description: PRIMARY OBJECTIVE:

I. To determine the rate of leptomeningeal failure after neoadjuvant radiation therapy (NaRT) versus (vs) postoperative stereotactic radiosurgery (SRS)/stereotactic radiation therapy (SRT).

SECONDARY OBJECTIVES:

I. Local control of brain metastases. II. Rate of salvage treatment including surgery, SRS, SRT, or whole brain radiation therapy (WBRT).

III. Dose and volume of radiation to adjacent normal brain parenchyma. IV. Rate of symptomatic radiation necrosis/steroid dependency. V. Rate of distant brain failure. VI. To compare overall survival (OS) between the 2 groups. VII. To determine the number of patients who die due to neurologic causes. VIII. To assess quality of life as assessed using Functional Assessment of Cancer Therapy?Brain (FACT?BR).

IX. To evaluate and compare the molecular makeup of tumor tissue in pre vs post radiation settings and determine differences in molecular and germline markers.

X. To evaluate biomarkers and germline markers predicting response.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo 1, 5, or 10 fraction of SRS/SRT radiation. Surgery is performed within 72 hours of radiation therapy.

ARM B: Within 2-5 weeks after standard of care surgery, patients undergo 1, 5, or 10 fraction of SRS/SRT.

After completion of study treatment, patients are followed up every 3 months.

Eligibility criteria: Inclusion Criteria:

* Prior histologic diagnosis of cancer other than small cell lung cancer, lymphoma, and germ cell histologies
* 1?4 cerebral metastases per magnetic resonance imaging (MRI) with at least 1 being dominant and eligible for resection
* No prior radiation treatment for the index brain metastases
* Systemic disease staged within previous 8 weeks and not rapidly progressing, with concern of life expectancy \> 3 months
* The patients will have been evaluated by the multidisciplinary team, and surgery must be deemed necessary as a result of indications including but not limited to mass effect or symptomatic lesion. Surgery must be deemed non?emergent or non?urgent clinically by the neurosurgeon
* Karnofsky performance status (KPS) \>= 70
* No active infections requiring systemic antibiotics
* If a woman is of childbearing potential, a negative serum pregnancy test must be documented. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study participation and for up to 4 weeks following the study treatment
* Ability to understand and willingness to sign a written informed consent

Exclusion Criteria:

* Patient deemed medically unfit to undergo surgical resection of brain metastasis
* Prior whole brain radiotherapy
* Patient with contraindication for imaging with MRI
* Surgery is considered emergent or urgent by the neurosurgeon due to symptoms or concerning mass effect noted on imaging
* Patients who are participating in a concurrent treatment protocol
* At the time of planning, unable to meet dose tolerance of the optic nerve/chiasm
* Tumor located in the brainstem
* Imaging or cytologic evidence of leptomeningeal disease
* Concurrent uncontrolled illness including, but not limited to, any of the following: Symptomatic congestive heart failure, unstable angina pectoris, psychiatric illness

Primary outcomes:
measure: Rate of leptomeningeal failure
timeFrame: Up to 2 years
Secondary outcomes:
measure: Time to progression
timeFrame: Up to 2 years
measure: Rate of salvage treatment including surgery, SRS, SRT, or WBRT
timeFrame: Up to 2 years
measure: Dose (Gy) and volume (cc) of radiation to adjacent normal brain parenchyma
timeFrame: Up to 2 years
measure: Rate of symptomatic radiation necrosis/steroid dependency
timeFrame: Up to 2 years
measure: Rate of distant brain failure
timeFrame: Up to 2 years
measure: Overall survival (OS)
timeFrame: Up to 2 years
measure: Death due to neurological causes
timeFrame: Up to 2 years
measure: Quality of life assessment: FACTBR
timeFrame: Up to 2 years
measure: Genetic expression profiles in pre vs post radiation tumor tissue
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA / Jonsson Comprehensive Cancer Center
state: California
Study officials:
affiliation: UCLA / Jonsson Comprehensive Cancer Center
name: Tania B Kaprealian, MD
role: PRINCIPAL_INVESTIGATOR
References: